Brief article
Patterns of prescription opioid abuse and comorbidity in an aging treatment population

Theodore J. Cicero, (Ph.D.)⁎, Hilary L. Surratt, (Ph.D.)b, Steven Kurtz, (Ph.D.)b, M.S. Ellis, (B.A.)a, James A. Inciardi, (Ph.D.)b,1

Received 8 April 2011; received in revised form 29 June 2011; accepted 5 July 2011

Abstract

Very little is known about the impact of age and gender on drug abuse treatment needs. To examine this, we recruited 2,573 opioid-dependent patients, aged from 18 to 75 years, entering treatment across the country from 2008 to 2010 to complete a self-administered survey examining drug use histories and the extent of comorbid psychiatric and physical disorders. Moderate to very severe pain and psychiatric disorders, including polysubstance abuse, were present in a significant fraction of 18- to 24-year-olds, but their severity grew exponentially as a function of age: 75% of those older than 45 years had debilitating pain and psychiatric problems. Women had more pain than men and much worse psychiatric issues in all age groups. Our results indicate that a “one-size-fits-all” approach to prevention, intervention, and treatment of opioid abuse that ignores the shifting needs of opioid-abusing men and women as they age is destined to fail. © 2012 Elsevier Inc. All rights reserved.

Keywords: Opioid abuse; Prescription drug abuse; Opioid treatment centers; Age-related changes in treatment needs; Age and gender influences on opioid treatment

1. Introduction

It is clear from many nationally based surveys and other studies that the “recreational” use of opioids for nontherapeutic purposes, that is, to get high, has shown major increases in the past 15 years or so, particularly in adolescents and young adults (Cai, Crane, Poneleit, & Paulozzi, 2010; Boyles, 2009; McCabe, Cranford, & West, 2008; Manchikanti, Fellows, Ailinani, & Pampati, 2010; Rogers & Copley, 2009; Skurtveit, Furu, Selmer, Handal, & Tverdal, 2010; Schulden, Thomas, & Compton, 2009). Although there is little systematic data available, it seems certain that only a small fraction of these first-time users will ultimately develop problematic use or abuse of prescription opioids. What distinguishes at-risk individuals from true recreational users who can use drugs occasionally with few negative effects is not fully understood. However, recent data indicate that those most likely to progress from misuse to abuse have significant levels of pain (often undertreated) and other medical and psychiatric comorbid conditions, including nicotine and alcohol abuse (Cicero et al., 2009; McCabe et al., 2008; Skurtveit et al., 2010; Sullivan, Edlund, Steffick, & Unützer, 2005; Sullivan, Edlund, Zhang, Unützer, & Wells, 2006). Given the extent of preexisting comorbidity and the ensuing disabilities inflicted by years of substance abuse, it seems logical to predict that, as they age, elderly substance abusers would be gravely ill.
Surprisingly, there have been very few published reports in which this has been examined. This could be related to a number of factors: first, reluctance of elderly patients to participate in research studies, particularly when deeply personal questions are asked (Buckwalter, 2009; Melberg & Humphreys, 2010; Papaleontiou et al., 2010; Tourangeau & Smith, 1996); second, lack of interest by researchers who believe that substance abuse is only a problem of the young; or, third, the inability to recruit substance-abusing older people since they are so few in numbers because of “burnout” or the severity of their comorbidity. No matter the reason, it remains clear that studies of abuse in older people remain greatly limited (Braden et al., 2010; Canfield et al., 2010; Dasgupta, Mandl, & Brownstein, 2009; Papaleontiou & Annest, 2007; Paulozzi, Ballesteros, & Stevens, 2006; Regier et al., 1990; Substance Abuse and Mental Health Services Administration Office of Applied Studies, 2010).

In an effort to study this “underserved” population, we recruited 2,573 patients, ranging in age from 18 to 75 years, entering drug treatment programs around the country whose primary drug was prescription opioid. Each of them completed an anonymous self-administered survey that covered a number of retrospective questions related to their history of use and abuse of opioids, current drug abuse problems, comorbid physical and psychiatric issues, and general physical/mental health.

2. Methods and methods

2.1. Survey of Key Informants’ Patients

The term key informants has been used for decades in sociological research and, in terms of our research, is defined as individuals who are well aware of drug abuse issues and patterns in their catchment area; they include researchers, ethnographers, and treatment specialists. In the current studies, all of the key informants were treatment center directors or their designees, who had daily contact with large numbers of patients who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for abuse/dependence on opioids. This ongoing nationwide survey, termed the Survey of Key Informants’ Patients (SKIP), is a key element of the postmarketing surveillance system: The Researched Abuse, Diversion and Addiction-Related Surveillance System (Cicero et al., 2007; Dart, 2009). Briefly, SKIP consists of more than 100 mostly privately funded treatment centers, balanced geographically (Cicero et al., 2007; Cicero, Inciardi, & Muñoz, 2005; Cicero, Surratt, & Inciardi, 2007), with a good representation of large urban, suburban, and rural treatment centers. Each of the treatment centers was asked to recruit patients/clients who had a diagnosis of opioid analgesic abuse or dependence using DSM-IV (American Psychiatric Association, 1994) diagnostic criteria and were just entering treatment (Cicero, Lynskey, Todorov, Inciardi, & Surratt, 2008).

2.2. Subject recruitment

Inclusion criteria for this study were very broad: first, subjects had to be 18 years or older (Institutional Review Board [IRB] requirement); second, they had to meet DSM-IV criteria for substance abuse whose primary drug was a prescription opioid (i.e., not heroin); and, third, they used prescription opioid drugs to get high at least once in the past 30 days prior to treatment. Overall, 85% of the patients approached by the treatment counselors completed and submitted surveys. The patients were asked to complete a detailed, self-administered survey instrument, covering demographics, licit and illicit patterns of drug use, diagnostic criteria for alcohol and opioid abuse or dependence using last 30 day use (DSM-IV criteria), the Fagerström test for nicotine dependence (Fagerstrom, 1978), general health status using the SF-36v2 Health Survey (Hawthorne, Osborne, Taylor, & Sansoni, 2007; Ware, Kosinski, & Dewey, 2001), and whether they were currently being treated for a psychiatric condition (Edlund et al., 2010).

2.3. SF-36 V2 health survey

With the release of SF-36v2, norms were calculated using data from the 1998 National Survey of Functional Health Status, and norm-based scoring algorithms were introduced (Hawthorne et al., 2007; Ware et al., 2001). Using this model, a T score of 50 ($SD = 10$) represents the average health status of all adults in this country. A score greater than 50 indicates better than normal health, whereas a score less than 50 represents poorer health. To control for the normal age- and gender-related differences in physical and mental health (e.g., presumably younger men and women would have T scores greater than 50—better physical health than the population as a whole), the SF-36v2 also calculates composite population scores for all men and women by age compared with the entire population. Thus, using age- and gender-appropriate composite scores, the impact of opioid abuse on the general physical and mental health status of men and women entering treatment can easily be assessed.

2.4. Measures

Other than the customary demographics (age, gender, ethnicity, employment status, and income), we obtained the composite physical and mental health scores from the well-validated SF-36v2, self-reported frequencies of psychiatric disorders that required treatment, pain scored from none to moderate severe, alcohol and nicotine dependence, and the means used to divert opioid medications from the normal medical supply chain.

2.5. Patient/subject confidentiality

Completed survey instruments were identified solely by a unique case number and were sent directly to the Washington
University School of Medicine. The treatment specialists did not see the detailed responses of their patients/clients. The protocol was approved by the Washington University IRB.

2.6. Data analyses

Data were analyzed using Predictive Analytics Software (formerly SPSS) version 18. Bivariate logistic regression models were developed to predict the influence of age and gender on demographics, diversion methods used to obtain prescription opioids, physical and mental health status, alcoholism, and nicotine dependence. The significance level was set at $p < .01$ for all comparisons.

3. Results

3.1. Demographics

As shown in Fig. 1, the frequency distribution of all 2,573 patients by age was an inverted U, bell-shaped curve with the peak at 25–34 years of age. After that, there was a sharp decline such that just 5% of the total population was older than 55 years. Given the low numbers of people older than 55 years ($n = 128$), in subsequent analyses, we pooled data from those 45 years or older into a single category ($n = 476$). The sample was predominately White (>80%). There were no gender- or age-related differences observed in ethnicity nor were there any ethnic differences observed on any dependent variable. Approximately equal numbers of males and females were present in each age group. Most were unemployed (>55%), but income levels for those who were employed were comparable to published rates for the general population.

3.2. Physical and mental health comorbidity

Fig. 2 shows the SF-36v2 physical and mental health composite scores (mean, 95% confidence interval [CI]) in opioid-abusing patients entering treatment compared with age- and gender-appropriate population norms. As they aged, both men and women entering treatment had increasingly poorer physical health composite scores than controls. However, the SF-36v2 mental health composite scores showed less deviation from population norms.

![Fig. 1. Percentage of the total population ($N = 2,573$) falling into the age brackets shown. The numbers in each age group are shown in italics on the y axis.](image1)

![Fig. 2. Mean (95% confidence limits) composite physical and mental health scores for males and females on the SF-36V2 health survey. Age-adjusted population norms, derived from large population studies carried out in validating the SF-36v2 instrument, for each age group are also shown.](image2)
scores, at close to 2 standard deviations from the norm, reflect even worse psychiatric health in aging males and particularly females who misuse opioids. Consistent with the global health analyses provided by the SF-36v2 composite scores, Fig. 3 breaks out several aspects of the many physical and mental health problems found in individuals with a primary diagnosis of substance abuse. Table 1 shows the odds ratios (ORs) for gender, and Table 2 shows the OR for age on all dependent variables. Moderate to very severe nonwithdrawal bodily pain, which interfered with work and social activities, was a prominent feature in those in the 18–24 age range, but this grew significantly with age such that the odds of those individuals older than 45 years having moderate to severe pain were two times greater than all other age groups (OR = 2.12, \( p < .001 \)). It is also apparent that the incidence of self-reported psychiatric disorders that required treatment was very high relative to published population norms in all ages, but the incidence grew with age: the odds of patients older than 45 years having a psychiatric disorder were significantly greater (OR = 1.601, \( p < .001 \)) than younger patients. Overall, the odds of women having psychiatric disorders were much greater than in males (Table 1; OR = 2.11, \( p < .001 \)). Fig. 3 also shows that there was considerable comorbid alcoholism and nicotine dependence in the treatment population. Rates of alcoholism were high in the youngest cohort of opioid-abusing patients but grew significantly with age: males and females older than 45 years had greater odds of alcoholism than younger patients (OR = 2.33, \( p < .001 \)). Nicotine dependence (i.e., smoking cigarettes) was also pervasive (Fig. 3). There were no clear gender differences in either rates of alcoholism or nicotine dependence.

3.3. Main source of primary drug

Fig. 4 shows age-related differences in the manner of diversion used to obtain prescription opioids. Dealers were used as a source of drugs by more than 70% of those 34 years or younger but showed an age-related decline such that the odds of individuals older than 45 years using a dealer were considerably lower than younger ages (Table 2; OR = 0.37, \( p < .001 \)). The odds of men using dealers were greater than females regardless of age (Table 1; OR = 1.380, \( p < .001 \)). In a seemingly compensatory fashion, the use of a doctor’s prescription as a source of drug showed precisely the opposite age-related pattern: very few men and women in the 18- to 24-year-old group used a legitimate medical channel to obtain drugs (Fig. 4), but this grew as a function of age such that males (OR = 2.31, \( p < .001 \)) and females (OR = 2.15, \( p < .001 \)) older than 45 years had much higher odds of using a doctor than younger men or women. Sharing was more common in women than men (Table 1; OR = 1.37, \( p < .001 \)) but showed an age-related nonsignificant decrease as a source of drugs in both genders. Theft or other illegal activity to obtain drugs was endorsed by relatively small numbers of young men and women, but the odds of women engaging in theft were greater than in men (Table 1; OR = 1.34, \( p < .008 \)) at all ages.

4. Discussion

Prescription opioid abuse in this country has become endemic over the past 15 years, which many believe was given momentum by two significant events: first, the release
and subsequent diversion of a sustained release preparation of oxycodone—OxyContin—which was falsely assumed by the company and the Food and Drug Administration to have low abuse potential (Cicero et al., 2005, 2008; General Accounting Office, U.S., 2003; Grant et al., 2004; Manchikanti et al., 2010; Schulden et al., 2009; Sproule, Brands, Li, & Catz-Biro, 2009), and, second, the Joint Commission on Accreditation of Healthcare Organizations’ report that named pain as the fifth vital sign and recommended that opioids be used much more (Manchikanti & Singh, 2008; Okie, 2010). This advice was obviously well received: The use of opioids surged after this highly publicized report, which inevitably resulted in some diversion for nontherapeutic purposes (Cicero et al., 2007). Aside from the debate on enabling factors, there is little doubt that prescription opioid abuse now dwarfs heroin abuse and, at least some other illegal drug use, as a public health problem in this country.

Our data show that moderate to severe non-withdrawal-related bodily pain—that greatly limited social contacts and work—was common in most of those entering treatment: 45% of those 18–24 years old reported moderate to severe pain. However, the incidence of this intense pain grew to well over 70% in individuals 45 years or older. The mental health status of men and, particularly, women entering treatment was even worse. Depression, anxiety, and polysubstance abuse (alcoholism and nicotine dependence) were already prevalent in our youngest sample at rates far greater than population norms, but mental health deteriorated rapidly, with the result that most of those older than 45 years were with psychiatric disorders. Although these observations are consistent with prior reports of comorbidity

Table 1
Bivariate logistic regressions evaluating the influence of gender on the dependent variables shown

<table>
<thead>
<tr>
<th>Variable</th>
<th>Females (n = 1,333)</th>
<th>Males (n = 1,240)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Source of primary opioid</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dealer</td>
<td>0.73 (0.62–0.85)</td>
<td>1.38 (1.18–1.62)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Medical</td>
<td>1.28 (1.10–1.50)</td>
<td>0.78 (0.67–0.91)</td>
<td>.002</td>
</tr>
<tr>
<td>Shared</td>
<td>1.37 (1.17–1.60)</td>
<td>0.73 (0.62–0.85)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Stolen</td>
<td>1.34 (1.08–1.67)</td>
<td>0.75 (0.60–0.92)</td>
<td>.008</td>
</tr>
<tr>
<td>Psychiatric disorder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>2.11 (1.80–2.47)</td>
<td>0.47 (0.40–0.56)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Anxiety</td>
<td>1.51 (1.21–1.89)</td>
<td>0.66 (0.53–0.83)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Bipolar</td>
<td>1.57 (1.23–2.10)</td>
<td>0.64 (0.50–0.82)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Depression</td>
<td>1.90 (1.47–2.44)</td>
<td>0.53 (0.41–0.68)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Other</td>
<td>0.91 (0.71–1.17)</td>
<td>1.10 (0.85–1.41)</td>
<td>.47</td>
</tr>
<tr>
<td>Physical health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate to severe pain in last 7 days</td>
<td>1.09 (0.93–1.28)</td>
<td>0.91 (0.78–1.07)</td>
<td>.26</td>
</tr>
<tr>
<td>Substance use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol dependence</td>
<td>0.86 (0.73–1.03)</td>
<td>1.16 (0.98–1.38)</td>
<td>.09</td>
</tr>
<tr>
<td>Nicotine dependence</td>
<td>1.24 (1.01–1.51)</td>
<td>0.81 (0.66–0.99)</td>
<td>.04</td>
</tr>
</tbody>
</table>

Note. Numbers in bold are statistically significant (a priori set at p < .01).

Table 2
Bivariate logistic regressions evaluating the influence of age in the dependent variables shown

<table>
<thead>
<tr>
<th>Variable</th>
<th>18–24 (n = 494)</th>
<th>25–34 (n = 998)</th>
<th>35–44 (n = 605)</th>
<th>45+ (n = 476)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Source of primary opioid</td>
<td>OR (95% CI)</td>
<td>p</td>
<td>OR (95% CI)</td>
<td>p</td>
</tr>
<tr>
<td>Dealer</td>
<td>2.05 (1.65–2.54)</td>
<td>&lt;.001</td>
<td>1.53 (1.30–1.81)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Medical</td>
<td>0.41 (0.33–0.50)</td>
<td>&lt;.001</td>
<td>0.89 (0.76–1.05)</td>
<td>.16</td>
</tr>
<tr>
<td>Shared</td>
<td>1.23 (1.01–1.49)</td>
<td>.04</td>
<td>1.11 (0.95–1.30)</td>
<td>.20</td>
</tr>
<tr>
<td>Stolen</td>
<td>1.40 (1.09–1.81)</td>
<td>.009</td>
<td>1.19 (0.96–1.48)</td>
<td>.11</td>
</tr>
<tr>
<td>Psychiatric disorder</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>0.68 (0.55–0.83)</td>
<td>&lt;.001</td>
<td>0.84 (0.72–0.99)</td>
<td>.03</td>
</tr>
<tr>
<td>Anxiety</td>
<td>0.64 (0.48–0.85)</td>
<td>&lt;.001</td>
<td>1.45 (1.15–1.83)</td>
<td>.002</td>
</tr>
<tr>
<td>Bipolar</td>
<td>0.82 (0.59–1.14)</td>
<td>.23</td>
<td>1.00 (0.79–1.28)</td>
<td>.10</td>
</tr>
<tr>
<td>Depression</td>
<td>0.52 (0.38–0.71)</td>
<td>&lt;.001</td>
<td>1.15 (0.89–1.50)</td>
<td>.29</td>
</tr>
<tr>
<td>Other</td>
<td>1.80 (1.32–2.45)</td>
<td>&lt;.001</td>
<td>1.15 (0.90–1.49)</td>
<td>.27</td>
</tr>
<tr>
<td>Physical health</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate to severe pain in last 7 days</td>
<td>0.53 (0.44–0.65)</td>
<td>&lt;.001</td>
<td>0.78 (0.67–0.92)</td>
<td>.003</td>
</tr>
<tr>
<td>Substance use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol dependence</td>
<td>0.58 (0.46–0.73)</td>
<td>&lt;.001</td>
<td>0.65 (0.54–0.78)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Nicotine dependence</td>
<td>0.57 (0.44–0.72)</td>
<td>&lt;.001</td>
<td>1.01 (0.83–1.24)</td>
<td>.89</td>
</tr>
</tbody>
</table>

Note. Numbers in bold are statistically significant (a priori set at p < .01).
in substance misusers (Cicero et al., 2009; McCabe et al., 2008; Skurtveit et al., 2010; Sullivan et al., 2005; Sullivan et al., 2006), the age and gender relatedness of these effects has not to our knowledge been fully appreciated until now. What seems clear is that treatment, prevention, and intervention programs would seem to be destined to fail if age and gender are not carefully considered in tailoring these efforts to specific populations.

Given the poor health we observed, it seems reasonable to postulate that disability, serious medical issues, and/or other factors (e.g., economic, risk aversion in seeking drugs—see below) would lead to the forced cessation of drug use in long-term substance abusers (i.e., “burnout”). If this is true, then one might expect, as we found, an age-related drop in drug-seeking behavior and in those seeking drug abuse treatment. However, it seems far more likely that, as they age, treatment for the medical complications associated with substance abuse (e.g., cognitive impairments, psychiatric disorders, organ failure, and so forth) may become much more clinically relevant than substance abuse treatment per se. Thus, a drop in the number of elderly people seeking drug treatment should not necessarily be assumed to indicate that the disease has run its course but that aging addicts end up in medical specialty treatment programs rather than drug treatment centers. In this connection, it should be noted that the comorbid conditions often associated with or caused by substance abuse are generally covered by insurance companies, whereas the public and private health insurance industry has become increasingly reluctant to cover substance abuse treatment per se in nearly any form. Thus, it could be that it is more economical and practical for patients and hospitals to treat the medical complications associated with abuse but not the underlying problem itself as the population of abusers age. We know of no studies in which this hypothesis has been systematically addressed.

As mentioned above, our study was not longitudinal, and it is therefore possible that the huge surge of youthful opioid-abusing patients who began using drugs in the 1993–2010 time frame have not yet reached the age of 40. If this hypothesis is correct, the number of elderly people seeking treatment should continue to rise over the next 5–10 years, which will represent a huge burden on drug treatment centers that are generally ill equipped to handle the plethora of serious psychiatric and physical ailments found in aging opioid-abusing patients.

As discussed above, we found in agreement with an earlier study that age and gender influenced the modes of diversion used to siphon drugs from medically appropriate channels to the illicit marketplace (Cicero, Ellis, Paradis, & Ortbl, 2010; Cicero, Kurtz, et al., 2010). At any age, women were much less likely to use a dealer than men, and, as they aged, both men and women were also more inclined to use medical channels as their primary source of drugs rather than dealers whose use predominates in younger men. These data could reflect the fact that women are much more risk averse than men and that, as they age, both men and women’s risk aversion makes doctors a much safer bet than dealers. However, other possibilities exist. Although it is certainly less risky to use a doctor than a dealer, the enhanced use of medical channels could be due to the fact that it is far easier for elderly patients with pain to get a doctor’s prescription for an analgesic than it would be for younger males and females to do so. In addition, it is also possible that it is much more economical, provided private- or government-funded insurance is available, to deal with a doctor rather than a dealer. Thus, at least some of the age-related inversion between dealers and doctors may be due to ease of access and economic concerns. Whichever explanation is correct, family practitioners, who prescribe the bulk of all opioids in the United States, should be just as cautious about potential opioid misuse in elderly persons as they might be for younger patients.

The largest confound in our studies is whether the comorbidity we observed is caused by the lengthy punishment inflicted by heavy substance abuse or if substance abuse is merely a symptom of a much larger constellation of psychiatric and physical problems, which grow worse with age, in a highly vulnerable subgroup of the general population. This confound probably can never be clearly resolved, but there is ample evidence (Manchikanti et al., 2010; McCabe et al., 2008; Rogers & Copley, 2009; Schulden et al., 2009; Skurtveit et al., 2010), including the present data, that adolescents and young adults who misuse opioids and other drugs have clear psychiatric and substance abuse (e.g., alcoholism) issues long before their misuse of opioids begins. This suggests that substance abuse is merely one symptom of a much larger constellation of problems and is not the causal factor in the poor physical and mental health we observed. However, it is difficult not to conclude that the deterioration in health over time is due, in some appreciable measure, to poor lifestyle choices including excessive opioid, alcohol, and other drug abuse issues.

There are limitations in our study. All of our surveys were self-administered, and thus, they have most of the problems
associated with these methods, particularly the inability to follow up answers with additional questions to clarify any ambiguities and truthfulness (Aquino & LoSciuto, 1990; Aquino, 1994; Hochstim, 1967). A second limitation is that our study population was confined to those entering treatment in many cases for the fourth or fifth time. Thus, this population, and their profound problems with drugs and other psychopathology, may be very different than less-ill, “recreational” drug users. Although all of these possibilities need to be kept in mind in interpreting our results, the anonymity provided by the self-administered questionnaire has been shown to produce much more candid and valid drug-related responses than interviewer-elicited information regarding substance abuse issues. Moreover, in a recently published study, it was found that the results of self-administered surveys and face-to-face interviews regarding sources of diversion were almost perfectly correlated (Cicero, Kurtz, et al., 2010).

References


